Skip to main content

Table 9 Subgroup analyses of primary end point for linagliptin versus total comparators based on proportional Cox hazards model and CMH test

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

  Linagliptin,patients with events/total patients Total comparators,patients with events/total patients Cox HR (95% CI) Incidence ratio (95% CI) CMH Test
Age (years)
≤50 5/1288 3/781 1.31 (0.31–5.58) 1.11 (0.47–2.63)
51 to <65 26/2817 26/1740 0.75 (0.43–1.30) 0.86 (0.52–1.41)
65 to 75 26/1418 29/902 0.78 (0.46–1.32) 0.84 (0.52–1.37)
≥75 3/324 4/189 0.63 (0.14–2.85) 0.88 (0.37–2.08)
Gender
Male 42/3183 50/2039 0.69 (0.45–1.04) 0.73 (0.49–1.08)
Female 18/2664 12/1573 1.22 (0.58–2.55) 1.27 (0.68–2.36)
Race     
White 46/3405 49/2190 0.78 (0.52–1.17) 0.83 (0.56–1.23)
Black 4/215 1/200 3.92 (0.44–35.08) 1.50 (0.55–4.11)
Asian 10/2227 12/1222 0.59 (0.25–1.37) 0.76 (0.39–1.49)
Use of rescue medication
No 43/5080 46/2824 0.70 (0.46–1.07) 0.75 (0.50–1.12)
Yes 17/767 16/788 1.10 (0.56–2.19) 1.11 (0.64–1.91)
Investigator-reported hypoglycemia
No 48/5197 37/2918 0.86 (0.56–1.32) 0.97 (0.65–1.45)
Yes 12/650 25/694 0.79 (0.39–1.59) 0.78 (0.41–1.47)
Framingham 10-year CV risk score
≤15% 20/3797 24/2438 0.65 (0.36–1.18) 0.76 (0.45–1.29)
>15% 36/1433 38/1046 0.85 (0.54–1.35) 0.91 (0.60–1.39)
Baseline microalbuminuria
Normal (≤30 mg/g) 25/3610 25/2389 0.84 (0.48–1.47) 0.91 (0.56–1.50)
Elevated (>30 to ≤300 mg/g) 21/1248 21/771 0.75 (0.41–1.38) 0.83 (0.49–1.41)
High (>300 mg/g) 6/280 14/241 0.43 (0.16–1.11) 0.63 (0.31–1.26)
  1. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; CMH test, Cochran-Mantel-Haenszel test with treatment arm continuity correction.